Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 2Liver Neoplasms 1Liver Diseases 1

Interventions

halofantrine 2Sorafenib 2trifluridine tipiracil drug combination 1trametinib 1toripalimab 1tislelizumab 1sintilimab 1rubitecan 1repotrectinib 1pevonedistat 1pembrolizumab 1ozanimod 1lenvatinib 1ledipasvir, sofosbuvir drug combination 1gadolinium ethoxybenzyl DTPA 1fisogatinib 1ficlatuzumab 1camrelizumab 1belinostat 1avelumab 1Trabectedin 1Shadowing Technique, Histology 1Ramucirumab 1Patient Navigation 1Oxaliplatin 1Nutritional Status 1Nivolumab 1Nadroparin 1N-monoacetylcystine 1Magnetic Resonance Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Liver Diseases × fisogatinib × Clear all
NCT02508467 2024-04-12

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Blueprint Medicines Corporation

Phase 1 Completed
146 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡